12:00 AM
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

LIPOchip regulatory update

The U.K.'s NICE issued draft guidance recommending against the use of the genetic tests Elucigene FH20 from Gen-Probe Inc. (NASDAQ:GPRO, San Diego, Calif.) and LIPOchip from Progenika Biopharma to confirm a clinical diagnosis of familial hypercholesterolemia ( FH), or for the screening of relatives for FH....

Read the full 235 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >